
    
      The purpose of this study is to assess the efficacy and safety include adverse events, vital
      signs, laboratory tests ,etc., of Chiauranib in ovarian cancer patients due to the outcomes
      of the phase I study, and to explore the relevance between the latent biomarkers of
      Chiauranib and clinical benefit.
    
  